These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25442382)

  • 1. [Pharmacology of the antifungals used in the treatment of aspergillosis].
    Azanza JR; Sádaba B; Gómez-Guíu A
    Rev Iberoam Micol; 2014; 31(4):255-61. PubMed ID: 25442382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis.
    Bellmann R
    Curr Pharm Des; 2013; 19(20):3629-47. PubMed ID: 23278532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
    Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
    Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacology of azoles].
    Azanza JR; García-Quetglas E; Sádaba B
    Rev Iberoam Micol; 2007 Sep; 24(3):223-7. PubMed ID: 17874860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
    Imai JK; Singh G; Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4063-6. PubMed ID: 15388482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.
    Brüggemann RJ; Antonius T; Heijst Av; Hoogerbrugge PM; Burger DM; Warris A
    Ther Drug Monit; 2008 Dec; 30(6):643-6. PubMed ID: 19057370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of current drug therapies for invasive aspergillosis.
    Traunmüller F; Popovic M; Konz KH; Smolle-Jüttner FM; Joukhadar C
    Pharmacology; 2011; 88(3-4):213-24. PubMed ID: 21986253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isavuconazole: Case Report and Pharmacokinetic Considerations.
    Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
    Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
    Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
    Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guideline based treatment of invasive aspergillosis].
    Karthaus M
    Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.
    Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on azole antifungals.
    Zonios DI; Bennett JE
    Semin Respir Crit Care Med; 2008 Apr; 29(2):198-210. PubMed ID: 18366001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
    Azanza Perea JR; Barberán J
    Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole versus amphotericin B for invasive aspergillosis.
    Blot F; Edé C; Nitenberg GM
    N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12490695
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
    Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
    Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic effects of aspergillosis management in high-risk patients.
    Leather H
    Manag Care Interface; 2005 Apr; 18(4):46-52. PubMed ID: 15889762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.